Clinical Trials

Multiple clinical trials spanning Phase 1 through Phase 4 have evaluated colestipol hydrochloride for managing hypercholesterolemia, hyperlipidemia, coronary atherosclerosis, accelerated teriflunomide elimination, erythropoietic protoporphyria, and diarrhea mitigation in HER2-positive breast cancer patients. Sponsored by pharmaceutical corporations, government institutes, and academic medical centers, these studies maintain recruitment statuses ranging from completed to terminated.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02400476 COMPLETED
Early Stage HER2+ Breast Cancer
Puma Biotechnology, Inc.
2015-02 PHASE2
NCT02263547 TERMINATED
Teriflunomide Elimination; Healthy Volunteers
Derrick Scott Robertson
2015-03 PHASE1
NCT02263547 Terminated
Teriflunomide Elimination|Healthy Volunteers
Derrick Scott Robertson|Genzyme a Sanofi Company|University of South Florida
2015-03 Phase 1
NCT01422915 COMPLETED
Erythropoietic Protoporphyria
Brigham and Women's Hospital
2011-05 PHASE2; PHASE3
NCT00203476 COMPLETED
Hyperlipidemia; Hypercholesterolemia
Tuscaloosa Research & Education Advancement Corporation
2005-05 PHASE4
NCT00000512 COMPLETED
Cardiovascular Diseases; Coronary Arteriosclerosis; Coronary Disease; Heart Diseases; Myocardial Ischemia
University of Washington
1984-01 PHASE3
NCT00000599 COMPLETED
Arterial Occlusive Diseases; Cardiovascular Diseases; Carotid Artery Diseases; Cerebral Arteriosclerosis; Cerebrovascular Disorders; Coronary Arteriosclerosis; Coronary Disease; Heart Diseases; Myocardial Ischemia; Atherosclerosis
National Heart, Lung, and Blood Institute (NHLBI)
1980-06 PHASE3

(data from https://clinicaltrials.gov, updated on 2022-05-06)

Check the Colestipol Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a high-molecular-weight anion-exchange resin, colestipol hydrochloride binds bile acids within the intestinal lumen to form an insoluble complex, thereby disrupting enterohepatic circulation and enhancing fecal bile excretion. This depletion stimulates hepatic conversion of endogenous cholesterol into bile acids and upregulates low-density lipoprotein receptors, effectively lowering serum cholesterol levels to manage hyperlipidemia and reduce cardiovascular risk.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.